Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonar...

Full description

Saved in:
Bibliographic Details
Published inJournal of Cancer Vol. 11; no. 11; pp. 3407 - 3415
Main Authors Tsiouda, Theodora, Sardeli, Chrisanthi, Porpodis, Konstantinos, Pilikidou, Maria, Apostolidis, Georgios, Kyrka, Krystallia, Miziou, Angeliki, Kyrka, Konstantina, Tsingerlioti, Zoi, Papadopoulou, Souzana, Heva, Anta, Koulouris, Charilaos, Giannakidis, Dimitrios, Boniou, Konstantina, Kesisoglou, Isaak, Vagionas, Anastasios, Kosmidis, Christoforos, Sevva, Christina, Papazisis, George, Goganau, Alexandru Marian, Sapalidis, Konstantinos, Tsakiridis, Kosmas, Tryfon, Stavros, Platanas, Michalis, Baka, Sofia, Zaric, Bojan, Perin, Branislav, Petanidis, Savvas, Zarogoulidis, Paul
Format Journal Article
LanguageEnglish
Published Australia Ivyspring International Publisher Pty Ltd 01.01.2020
Ivyspring International Publisher
Subjects
Online AccessGet full text

Cover

Loading…
Abstract : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. : Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. : 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. : The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death.
AbstractList Introduction : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. Materials & Methods : Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. Results : 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. Conclusions : The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death.
: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. : Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. : 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. : The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death.
Introduction: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. Materials & Methods: Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. Results: 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. Conclusions: The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death.
Author Goganau, Alexandru Marian
Pilikidou, Maria
Kyrka, Konstantina
Kesisoglou, Isaak
Papazisis, George
Heva, Anta
Baka, Sofia
Papadopoulou, Souzana
Platanas, Michalis
Petanidis, Savvas
Porpodis, Konstantinos
Tryfon, Stavros
Boniou, Konstantina
Kyrka, Krystallia
Sardeli, Chrisanthi
Kosmidis, Christoforos
Sapalidis, Konstantinos
Zaric, Bojan
Koulouris, Charilaos
Tsakiridis, Kosmas
Miziou, Angeliki
Tsiouda, Theodora
Giannakidis, Dimitrios
Apostolidis, Georgios
Zarogoulidis, Paul
Sevva, Christina
Tsingerlioti, Zoi
Perin, Branislav
Vagionas, Anastasios
AuthorAffiliation 3 Pulmonary Department, G. “Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
5 General Surgery Clinic 1, University of Medicine and Pharmacy of Craiova, Craiova County Emergency Hospital, Craiova, Romania
7 Pulmonary Department (NHS), G.H. “G. Papanikolaou” Thessaloniki, Thessaloniki, Greece
1 Pulmonary Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece
4 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
8 Urology Department (NHS), General Hospital of Giannitsa, Giannitsa, Greece
6 Thoracic Surgery Department, “Interbalkan” European Medical Center, Thessaloniki, Greece
2 Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
9 Oncology Department, “Interbalkan” European Medical Center, Thessaloniki, Greece
10 Institute for Pulmonary Diseases of Vojvodina, Facu
AuthorAffiliation_xml – name: 1 Pulmonary Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece
– name: 5 General Surgery Clinic 1, University of Medicine and Pharmacy of Craiova, Craiova County Emergency Hospital, Craiova, Romania
– name: 2 Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
– name: 10 Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
– name: 6 Thoracic Surgery Department, “Interbalkan” European Medical Center, Thessaloniki, Greece
– name: 7 Pulmonary Department (NHS), G.H. “G. Papanikolaou” Thessaloniki, Thessaloniki, Greece
– name: 4 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– name: 8 Urology Department (NHS), General Hospital of Giannitsa, Giannitsa, Greece
– name: 3 Pulmonary Department, G. “Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
– name: 9 Oncology Department, “Interbalkan” European Medical Center, Thessaloniki, Greece
– name: 11 Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Author_xml – sequence: 1
  givenname: Theodora
  surname: Tsiouda
  fullname: Tsiouda, Theodora
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 2
  givenname: Chrisanthi
  surname: Sardeli
  fullname: Sardeli, Chrisanthi
  organization: Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
– sequence: 3
  givenname: Konstantinos
  surname: Porpodis
  fullname: Porpodis, Konstantinos
  organization: Pulmonary Department, G. "Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
– sequence: 4
  givenname: Maria
  surname: Pilikidou
  fullname: Pilikidou, Maria
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 5
  givenname: Georgios
  surname: Apostolidis
  fullname: Apostolidis, Georgios
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 6
  givenname: Krystallia
  surname: Kyrka
  fullname: Kyrka, Krystallia
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 7
  givenname: Angeliki
  surname: Miziou
  fullname: Miziou, Angeliki
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 8
  givenname: Konstantina
  surname: Kyrka
  fullname: Kyrka, Konstantina
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 9
  givenname: Zoi
  surname: Tsingerlioti
  fullname: Tsingerlioti, Zoi
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 10
  givenname: Souzana
  surname: Papadopoulou
  fullname: Papadopoulou, Souzana
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 11
  givenname: Anta
  surname: Heva
  fullname: Heva, Anta
  organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece
– sequence: 12
  givenname: Charilaos
  surname: Koulouris
  fullname: Koulouris, Charilaos
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 13
  givenname: Dimitrios
  surname: Giannakidis
  fullname: Giannakidis, Dimitrios
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 14
  givenname: Konstantina
  surname: Boniou
  fullname: Boniou, Konstantina
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 15
  givenname: Isaak
  surname: Kesisoglou
  fullname: Kesisoglou, Isaak
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 16
  givenname: Anastasios
  surname: Vagionas
  fullname: Vagionas, Anastasios
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 17
  givenname: Christoforos
  surname: Kosmidis
  fullname: Kosmidis, Christoforos
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 18
  givenname: Christina
  surname: Sevva
  fullname: Sevva, Christina
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 19
  givenname: George
  surname: Papazisis
  fullname: Papazisis, George
  organization: Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
– sequence: 20
  givenname: Alexandru Marian
  surname: Goganau
  fullname: Goganau, Alexandru Marian
  organization: General Surgery Clinic 1, University of Medicine and Pharmacy of Craiova, Craiova County Emergency Hospital, Craiova, Romania
– sequence: 21
  givenname: Konstantinos
  surname: Sapalidis
  fullname: Sapalidis, Konstantinos
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
– sequence: 22
  givenname: Kosmas
  surname: Tsakiridis
  fullname: Tsakiridis, Kosmas
  organization: Thoracic Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece
– sequence: 23
  givenname: Stavros
  surname: Tryfon
  fullname: Tryfon, Stavros
  organization: Pulmonary Department (NHS), G.H. "G. Papanikolaou" Thessaloniki, Thessaloniki, Greece
– sequence: 24
  givenname: Michalis
  surname: Platanas
  fullname: Platanas, Michalis
  organization: Urology Department (NHS), General Hospital of Giannitsa, Giannitsa, Greece
– sequence: 25
  givenname: Sofia
  surname: Baka
  fullname: Baka, Sofia
  organization: Oncology Department, "Interbalkan" European Medical Center, Thessaloniki, Greece
– sequence: 26
  givenname: Bojan
  surname: Zaric
  fullname: Zaric, Bojan
  organization: Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
– sequence: 27
  givenname: Branislav
  surname: Perin
  fullname: Perin, Branislav
  organization: Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
– sequence: 28
  givenname: Savvas
  surname: Petanidis
  fullname: Petanidis, Savvas
  organization: Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
– sequence: 29
  givenname: Paul
  surname: Zarogoulidis
  fullname: Zarogoulidis, Paul
  organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32231747$$D View this record in MEDLINE/PubMed
BookMark eNpdkU9P3DAQxa2KqtAtB74AssSlPQRsjx3HFyQUaEFa0QNwtpzshM1qY2_thMK3r8ufFa0P49HMT09v9D6THR88EnLA2bHmip2sWncsGTflB7LHK9CFKUu5867fJfsprVh-YISW8InsghDAtdR7pL_BR3redx1G9C0m6vyCni0eMCakF3ncjok2OP5G9LRe4hDGJUa3eXoGr4Zh8ttJFyK9Dr64Gdx6TWvMZT75e1q7rBy_kI-dWyfcf_1n5O77xW19Wcx__riqz-ZFKxmMRdUKo1TJuWaN0h2KygFq1QkEAQ0o6QyohRAdY4YzANVoaBoFEplEgyXMyOmL7mZqBly06Mfo1nYT-8HFJxtcb__d-H5p78OD1cxokz3MyNdXgRh-TZhGO_Spzdc4j2FKVkClhM4eTUaP_kNXYYo-n2eFMhVIVpUyU99eqDaGlCJ2WzOc2b8Z2pyhfc4ws4fv3W_Jt8TgDxtBmCo
CitedBy_id crossref_primary_10_3389_fmolb_2023_1297198
crossref_primary_10_1016_j_bulcan_2023_02_010
crossref_primary_10_1080_14740338_2023_2243220
crossref_primary_10_1016_j_intimp_2023_109713
crossref_primary_10_3389_fonc_2023_1210297
crossref_primary_10_3389_fonc_2024_1307836
crossref_primary_10_1002_cnr2_1739
crossref_primary_10_1016_j_jmb_2021_167221
crossref_primary_10_1155_2021_8852261
crossref_primary_10_3390_curroncol29110637
crossref_primary_10_3390_medicina58121779
crossref_primary_10_1371_journal_pone_0240633
ContentType Journal Article
Copyright The author(s).
2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The author(s) 2020
Copyright_xml – notice: The author(s).
– notice: 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The author(s) 2020
DBID NPM
AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.7150/jca.40196
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Health Medical collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X7
  name: ProQuest_Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1837-9664
EndPage 3415
ExternalDocumentID 10_7150_jca_40196
32231747
Genre Journal Article
GroupedDBID ---
53G
5VS
7X7
8FI
8FJ
ABDBF
ABUWG
ADBBV
ADRAZ
AENEX
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
DIK
E3Z
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IPNFZ
KQ8
M48
M~E
NPM
O5R
O5S
OK1
PGMZT
PIMPY
RIG
RPM
UKHRP
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c403t-8c295561170b57fe28a3e75f2e323b354a935d22f00910335b73bb534e04e9e63
IEDL.DBID RPM
ISSN 1837-9664
IngestDate Tue Sep 17 21:28:06 EDT 2024
Fri Aug 16 00:46:30 EDT 2024
Thu Oct 10 19:30:57 EDT 2024
Fri Aug 23 01:26:21 EDT 2024
Sat Sep 28 08:28:18 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords adverse effects
chemotherapy
Lung cancer
immunotherapy
Language English
License The author(s).
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c403t-8c295561170b57fe28a3e75f2e323b354a935d22f00910335b73bb534e04e9e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interest exists.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097940/
PMID 32231747
PQID 2598340864
PQPubID 5263174
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7097940
proquest_miscellaneous_2385275569
proquest_journals_2598340864
crossref_primary_10_7150_jca_40196
pubmed_primary_32231747
PublicationCentury 2000
PublicationDate 2020-01-01
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – month: 01
  year: 2020
  text: 2020-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Australia
PublicationPlace_xml – name: Australia
– name: Wyoming
– name: Sydney
PublicationTitle Journal of Cancer
PublicationTitleAlternate J Cancer
PublicationYear 2020
Publisher Ivyspring International Publisher Pty Ltd
Ivyspring International Publisher
Publisher_xml – name: Ivyspring International Publisher Pty Ltd
– name: Ivyspring International Publisher
SSID ssj0000392743
Score 2.320233
Snippet : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by...
Introduction: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are...
Introduction : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 3407
SubjectTerms Anemia
Asthma
Autoimmune diseases
Cancer therapies
Cardiovascular disease
Chemotherapy
Chronic illnesses
Chronic obstructive pulmonary disease
Diabetes
Gastroesophageal reflux
Gender
Gene expression
Heart failure
Hypertension
Hyperthyroidism
Hypothyroidism
Immunotherapy
Infections
Kinases
Ligands
Lung cancer
Patients
Research Paper
Stroke
Ultrasonic imaging
Womens health
SummonAdditionalLinks – databaseName: Health Medical collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9wwDLcYSNNeEGMbFG5TmPbakeajaZ8QOkA3xN0LQ7q3Kml9AgQ94A4J_nucNtftQOKlD02qtnZs_2I7NsCv1EeHnONxKZSOlXMmdrkmcbc2EWlOMtKUzB-O0sGFOh3rcXC4zUJa5UInNoq6mpbeR75PMD2TigC4Ori7j33XKB9dDS00PsBaInjqU7rM2HQ-Fk7GnyxkW1DIEPTZvy7tb-VLwiyboTfY8nWK5H8252QD1gNYZIctdz_DCtab8HEYwuFf4Oocn9hRaHFCAs9sXbGmxfIMWVuXeMZCJhbzpQHCcavnZuIffzSku0PglY2mdXx-a29uWB_pckaKgPX9snj4Chcnx3_7gzj0TohLxeU8zkqR-86XieFOmwmKzEo0eiJQCumkVjaXuhJiwj1gkFI7I53TUiFXmGMqv8FqPa1xG1hlSl4lmFhUmRKWnkabTQhHGoEEL2UEPxekLO7aEhkFbS08vQuid9HQO4LegshFkJJZ8Y-nEex1w7S-fdDC1jh9pDky08LQr-QRbLU86d5CyojgjzIRmCVudRN87ezlkfrqsqmhbXhOmojvvP9Zu_BJ-P1143Lpwer84RG_EwiZux_NSnsBA9Lc4Q
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3JTsMwEB2VIiEuiJ2wySCugdRLnJwQKqCCgAtU4hbZ7VQUlRS6SPTvGSduRYEDlxxiW1bG9vi9ePwG4CR2p0PWRmGLSxVKa3VoU0XL3Zgaj1NaI4Vk_v1D3GjK22f1XIFpjk1vwOGf1M7lk2oOeqefH5NzWvCEX0814ZmzV-L-0um8LMAil0TQXQSfR_mFQyYM4EPtiY45PUpZagzNt57fmX7BzZ9Rk9-2oetVWPH4kV2UA74GFczXYenen5BvQPcRP9mlz3pCPoCZvM2KrMtDZKVU8ZD54Czm1AL8DaxJUfHG3RaZvSE8yx76efj4Zno9Vkd63JFvYHU3Uwab0Ly-eqo3Qp9OIWzJSIzCpMVTlwyzpiOrdAd5YgRq1eEouLBCSZMK1ea8EzkMIYSyWlirhMRIYoqx2IJq3s9xB1hbt6J2DWsGZSK5odZokg5BS82REKcI4Hhqyuy9VM3IiG04e2dk76ywdwD7UyNn03HPiI0lQhLPkgEczYppyrtzDJNjf0x1RKK4pk9JA9gux2TWC_knQkRSB6DnRmtWwclpz5fk3ZdCVltHKTmnaPcf_e7BMne8u_gVsw_V0WCMBwRORvawmHpffNbiiA
  priority: 102
  providerName: Scholars Portal
Title Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/32231747
https://www.proquest.com/docview/2598340864
https://search.proquest.com/docview/2385275569
https://pubmed.ncbi.nlm.nih.gov/PMC7097940
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB4VkBCXFe_NwlYG7TVt6kedHHe7rQDRCm1B6i2y06koalNEi7T773fsJFWBGxcfEltJxt94ZuLxNwA_2m53yNoozLhUobRWhzZRpO7GtHg7IR3xlPn9QfvqQd6M1KgGqjoL45P2Mztt5LN5I58--tzK53nWrPLEmnf9jo4SglHU3IItAuhGiO6XX7L4ZBYLFiFN_k7zKTMN6Xhg9mCX8EsW0xVT2TRDH3zL9ymSGzantw9fSmeR_Sxe6gBqmB_Cbr_cDj-C6RD_st9liRNSeGbyMfMllpfICl7iJSszsZijBiiPW_3zHa_d0ZD1FXJe2WCRh8O5mc1YB6m5pYWAdRwsXo7hode971yFZe2EMJORWIVxxhNX-bKlI6v0BHlsBGo14Si4sEJJkwg15nwSOYdBCGW1sFYJiZHEBNviBLbzRY5fgY11Fo1b2DIoY8kNjUYTT8iP1BzJvRQBXFaiTJ8LioyUQgsn-pREn3rRB3BeCTkttWSZUugVC0lBlQzgYn2b8O02LUyOi1fqI2LFNX1KEsBpMSfrp1STGYB-M1vrDo47--0dgpTn0C4h9O3TI89gj7vQ2_-NOYft1csrfif_ZGXrhMqRrsPOr-7g7k_dR_nU9mVc90j9DyON6h0
link.rule.ids 230,315,730,783,787,867,888,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7xkEoviEdpw9OgXlO8fqyTE0ILaGl39wJIe4vsZFYFQZayi1T-PePEG7pF4pJD7CjJjGf8ecb-BuB722eHnONxLpSOlXMmdqkmc7e2Jdop2UhFmd8ftLs36udQD0PAbRK2Vc58YuWoi3HuY-THBNMTqQiAq5PHP7GvGuWzq6GExiIsex4uX8HADE0TY-E0-dMMWRMKGYI-x3e5_aE8Jcz8NPQOW_6_RfKfOediDVYDWGSntXbXYQHLDfjUD-nwTbi9wr_sLJQ4IYNntixYVWJ5gqzmJZ6wsBOLeWqAcNzqpep46Y-GNHcIvLLBuIyvHuz9PesgXXrkCFjHD4unL3BzcX7d6cahdkKcKy6ncZKL1Fe-bBnutBmhSKxEo0cCpZBOamVTqQshRtwDBim1M9I5LRVyhSm25RYsleMSvwErTM6LFrYsqkQJS0-jTUaEI41AgpcygqOZKLPHmiIjo6WFl3dG8s4qeUewOxNyFqxkkr3pNILDppnGt09a2BLHz9RHJloY-pU0gq-1Tpq3kMYJ_igTgZnTVtPBc2fPt5S3vysObcNT8kR8--PPOoCV7nW_l_UuB7924LPwa-0q_LILS9OnZ9wjQDJ1-9WoewV54N_I
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJ1W8IMZnYAODeA11_REnT9PWrWphqyrGpL1FdnIRQyMdayex_37nxM0oSLzkIXaU5O58_tl3_h3Ax8RHh5zjcSGUjpVzJnaZpuFu7VAkGY2RhjL_ZJZMztTnc30e8p-WIa1y7RMbR10uCr9HPiCYnkpFAFwNqpAWMT8c7139in0FKR9pDeU0HsKWUYnkPdg6OJrNv3Y7LpygAM2XLb2QISA0-FHYT8oTxGxOSv8gzb8TJv-YgcZP4HGAjmy_1fU2PMD6KfRPQnD8GVyc4m92GAqe0PBnti5ZU3B5iaxlKV6ykJfFPFFAOHx123Sc-oMi3R2Csmy2qOPTn_byko2QLsfkFtjIG8n1czgbH30bTeJQSSEuFJerOC1E5utgDg132lQoUivR6EqgFNJJrWwmdSlExT18kFI7I53TUiFXmGEiX0CvXtT4ClhpCl4OcWhRpUpYehptWhGqNAIJbMoIPqxFmV-1hBk5LTS8vHOSd97IO4KdtZDzMGaW-b2GI3jfNZO1-xCGrXFxQ31kqoWhX8kieNnqpHsLuSYCQ8pEYDa01XXwTNqbLfXF94ZR2_CM_BJ__f_Pegd9Mrn8eDr78gYeCb_wbvZidqC3ur7BXUInK_c2mN0dnOLlZQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sex+Differences+and+Adverse+Effects+between+Chemotherapy+and+Immunotherapy+for+Non-Small+Cell+Lung+Cancer&rft.jtitle=Journal+of+Cancer&rft.au=Tsiouda%2C+Theodora&rft.au=Sardeli%2C+Chrisanthi&rft.au=Porpodis%2C+Konstantinos&rft.au=Pilikidou%2C+Maria&rft.date=2020-01-01&rft.issn=1837-9664&rft.eissn=1837-9664&rft.volume=11&rft.issue=11&rft.spage=3407&rft.epage=3415&rft_id=info:doi/10.7150%2Fjca.40196&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1837-9664&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1837-9664&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1837-9664&client=summon